<DOC>
	<DOCNO>NCT00460408</DOCNO>
	<brief_summary>The study provide additional safety data specific safety event person receive intravitreal injection . The Committee Medicinal Products Human Use ( CHMP ) interest obtain additional safety information Macugen use real world settings practitioner Europe treat patient neovascular ( wet ) age-related macular degeneration ( AMD ) . The study provide information physician practice pattern characteristic patient treat Macugen .</brief_summary>
	<brief_title>Ocular Safety Of Patients Receiving Macugen For Neovascular Age Related Macular Degeneration</brief_title>
	<detailed_description>No comparator Patients age-related macular degeneration</detailed_description>
	<mesh_term>Macular Degeneration</mesh_term>
	<mesh_term>Wet Macular Degeneration</mesh_term>
	<criteria>Neovascular AMD patient eligible Macugen therapy base approve label Active suspect ocular periocular infection . Known hypersensitivity active substance excipients .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Macular degeneration</keyword>
	<keyword>Safety</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Non-randomized</keyword>
</DOC>